CRVS Return on Tangible Equity | Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. (CRVS) Return on Tangible Equity

2026-06-30: Return Tang Equity -24.02%.
2026-03-31: Return Tang Equity -18.35%.
2025-12-31: Return Tang Equity -24.97%.
2025-09-30: Return Tang Equity -21.01%.

Complete source-backed return tang equity history.

Available history: 2014-12-31 to 2026-06-30
Data captured: 2026-09-04

Historical Return Tang Equity

Date	Return Tang Equity
2026-06-30	-24.02%
2026-03-31	-18.35%
2025-12-31	-24.97%
2025-09-30	-21.01%
2025-06-30	-56.26%
2025-03-31	-83.93%
2024-12-31	-191.27%
2024-09-30	-458.00%
2024-06-30	-44.15%
2024-03-31	-74.50%
2023-12-31	-69.87%
2023-09-30	-68.17%
2023-06-30	-78.86%
2023-03-31	-83.66%
2022-12-31	-73.61%
2022-09-30	-62.97%
2022-06-30	-45.49%
2022-03-31	-44.54%
2021-12-31	-44.50%
2021-09-30	-6.33%
2021-06-30	-6.00%
2021-03-31	-4.92%
2020-12-31	-8.31%
2020-09-30	-104.81%
2020-06-30	-89.69%
2020-03-31	-79.89%
2019-12-31	-65.63%
2019-09-30	-57.37%
2019-06-30	-50.89%
2019-03-31	-43.97%
2018-12-31	-42.54%
2018-09-30	-40.69%
2018-06-30	-39.70%
2018-03-31	-39.30%
2017-12-31	-65.61%
2017-09-30	-58.48%
2017-06-30	-50.01%
2017-03-31	-38.96%
2016-12-31	-27.39%
2016-09-30	-21.92%
2016-06-30	-15.91%
2016-03-31	-23.45%
2015-12-31	100.75%

Annual Return Tang Equity

Date	Return Tang Equity
2025-12-31	-24.97%
2024-12-31	-191.27%
2023-12-31	-69.87%
2022-12-31	-73.61%
2021-12-31	-44.50%
2020-12-31	-8.31%
2019-12-31	-65.63%
2018-12-31	-42.54%
2017-12-31	-65.61%
2016-12-31	-27.39%
2015-12-31	100.75%
2014-12-31	101.26%

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Janux Therapeutics, Inc. (JANX)	United States	$1.019B	-9.15
Pacira BioSciences, Inc. (PCRX)	United States	$1.020B	69.03
Kura Oncology, Inc. (KURA)	United States	$0.967B	-3.29
Arbutus Biopharma Corp (ABUS)		$0.965B	6.19
MoonLake Immunotherapeutics (MLTX)	Switzerland	$1.031B	-5.43
Savara Inc (SVRA)	United States	$1.044B	-9.10
Jade Biosciences, Inc. (JBIO)	United States	$0.936B	-9.21
MANNKIND CORP (MNKD)	United States	$1.058B	-30.41
Alto Neuroscience, Inc. (ANRO)	United States	$1.065B	-11.02
Apnimed, Inc. (APMD)	United States	$0.899B